Navigation Links
Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Date:1/29/2008

PT. RICHMOND, Calif., Jan. 29 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, President & Chief Executive Officer, will present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference at the Grand Hyatt Hotel in New York City on Tuesday, February 5, 2008 at 8:40 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to file an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
2. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
3. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
4. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
5. Amylin Pharmaceuticals Reports 2007 Financial Results
6. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
7. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
8. Wyeth and Teva Pharmaceuticals Extend the Standstill Period Relating to Tevas Launch of Generic Pantoprazole
9. Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed
10. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
11. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Bensonhurst, NY (PRWEB) , ... May 23, 2016 , ... ... Enrico Ferdico took the time to summarize the weight loss process: , New patients ... a Body Composition Analysis (BCA) to get accurately evaluated. , Body Composition Analysis, There ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an article published May ... massive role in oral health and hygiene. The article points out that, as long as ... their toothbrushes will become worn and frayed. Of course, these worn-out bristles won’t clean teeth ...
(Date:5/23/2016)... , ... May 23, 2016 , ... According to an ... in an exuberant mood since the birth of her son, Rockwell Lloyd Liu, and ... ever had.” The “Elementary” and “Kill Bill” star explains that, as a career oriented ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical Data ... from the Japan PMDA, US FDA, industry and academia at the 2016 ... format data from clinical trials so that it can be shared and compared, ...
(Date:5/23/2016)... ... ... NYDNRehab, a New York City-based physical therapy clinic , is introducing ... type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of University ... With over 10 million sport injuries per year in the United States, ...
Breaking Medicine News(10 mins):
(Date:5/22/2016)... 23, 2016 DS Biopharma ... and anti-inflammatory compound DS102 in chronic obstructive pulmonary ... steatohepatitis (NASH) patients. Recent DS preclinical ... lung tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic ... The Company will publish further detail on these ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:5/19/2016)... Oregon , May 19, 2016 ... titled, World Medical/Diagnostic Imaging Market -Opportunities and Forecasts, 2015 ... reach $45.0 billion by 2022, registering a CAGR of ... expected to continue to be the highest revenue-generating segment ... accounted for around one-third of the market share ...
Breaking Medicine Technology: